First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

• Drug: AG-013736
  
  Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
• Drug: AG-013736
  
  Axitinib continuous oral dosing (20 mg twice a day) in the fed state
• Drug: AG-013736
  
  Axitinib continuous oral dosing (5 mg twice a day) in the fed state
• Drug: AG-013736
  
  Axitinib continuous oral dosing (15 mg once a day) in the fed state
• Drug: AG-013736
  
  Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
• Drug: AG-013736
  
  Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state

• Experimental: Cohort 1
  
  Intervention: Drug: AG-013736
• Experimental: Cohort 2
  
  Intervention: Drug: AG-013736
• Experimental: Cohort 3
  
  Intervention: Drug: AG-013736
• Experimental: Cohort 4
  
  Intervention: Drug: AG-013736
• Experimental: Cohort 5
  
  Intervention: Drug: AG-013736
• Experimental: Cohort 6
  
  Intervention: Drug: AG-013736

Inclusion Criteria:

• Patients with cytologically or histologically confirmed solid tumor(s) and with at least one measurable disease site
• Patients with adequate bone marrow, liver and kidney function
• Patients with life expectancy of at least 12 weeks

Exclusion Criteria:

• Patients who have received chemotherapy, immunotherapy, radiotherapy or any investigational agent within 4 weeks of study entry
• Patients with have had a major surgical procedure within 4 weeks of study entry